The impact of inactivation of the GH/IGF axis during aging on healthspan.

Sher Bahadur Poudel, Ryan R Ruff, Zhiming He, Manisha Dixit, Godze Yildirim, Hashan Jayarathne, Dulmalika Herath Manchanayake, Jelena Basta-Pljakic, Silvana Duran-Ortiz, Mitchell B Schaffler, John J Kopchick, Marianna Sadagurski, Shoshana Yakar

David B. Kriser Dental Center, Department of Molecular Pathobiology, New York University College of Dentistry, 345 East 24Th Street, New York, NY, 10010-4086, USA.David B. Kriser Dental Center, Department of Molecular Pathobiology, New York University College of Dentistry, 345 East 24Th Street, New York, NY, 10010-4086, USA. · pubmed

Paper

Abstract

Several mouse lines with congenital growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis disruption have shown improved health and extended lifespan. The current study investigated how inactivating this axis, specifically during aging, impacts the healthspan. We used a tamoxifen-inducible global GH receptor (GHR) knockout mouse model starting at 12 months and followed the mice until 24 months of age (iGHRKO

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper investigates the role of the GH/IGF axis in aging and its inactivation's effects on healthspan, which is directly related to longevity research. The findings could contribute to understanding mechanisms that influence aging and lifespan extension. However, while the study presents important insights, it does not appear to introduce groundbreaking concepts or methodologies that would significantly advance the field, hence the moderate impact score.

Author of this paper? Send a correction.